A5342: Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
Study Location:
Baltimore
Topic:
HIV
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT02411539?term=A5342&rank=1
Coordinator:
Ilene Wiggins, RN
Enrollment:
Closed
Trial Period:
Completed
The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody (mAb), VRC-HIVMAB060-00-AB (VRC01), in adults infected with HIV who are receiving antiretroviral therapy (ART).
Ages Eligible for Study: 18 Years to 65 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
410-614-2766
iwiggin1@jhmi.edu